Silence Therapeutics Plc American Depository Share (SLN) Stock
Key stats
- Market cap
- $558.14M
- Price / Earnings ratio
- -7.0x
- EPS (TTM)
- -$1.32
- Volume
- Loading
- 52-week high
- $17.58
- 52-week low
- $4.19
Source: third-party data provider, as of October 16, 2026
Compare with SLN
Recent news

Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
SLN

Silence Therapeutics (SLN) Upgraded to Buy: Here's Why
Silence Therapeutics (SLN) Upgraded to Buy: Here's Why
SLN

Silence Therapeutics to Participate in Three September Investor Conferences
Silence Therapeutics to Participate in Three September Investor Conferences
SLN

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
SLN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 24.38
- MACD 12/26/9
- -0.92
- EMA 9 of MACD
- -0.78
- MACD histogram
- -0.15
- SMA 50
- $12.41
- Price below SMA 50
- EMA 50
- $11.30
- Price below EMA 50
- SMA 200
- $8.34
- Price above SMA 200
- EMA 200
- $9.00
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
SLN

Silence Therapeutics (SLN) Upgraded to Buy: Here's Why
Silence Therapeutics (SLN) Upgraded to Buy: Here's Why
SLN

Silence Therapeutics to Participate in Three September Investor Conferences
Silence Therapeutics to Participate in Three September Investor Conferences
SLN

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
SLN

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know
SLN

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
SLN

Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
SLN

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
SLN

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
SLN

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
SLN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D | Interim CEO & Chairman of the Board | 1954 |
| Ms. Rhonda L. Hellums | Executive VP, CFO, Secretary & Executive Director | 1971 |
| Dr. Steven J. Romano M.D. | Executive VP and Chief Research & Development Officer | 1959 |
| Dr. Marie Wikstrom Lindholm Ph.D. | Chief Scientific Officer | — |
| Ms. Gem Gokmen Hopkins | Head of IR & Corporate Communications | — |
| Mr. Jaimin B. Shah | SVP & General Counsel | — |
| Mr. J.P. Gabriel | Chief Technical Operations Officer | — |
| Mr. Curtis Rambaran M.D. | Chief Medical Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 16, 2026
Technical indicators
- RSI 14
- 24.38
- MACD 12/26/9
- -0.92
- EMA 9 of MACD
- -0.78
- MACD histogram
- -0.15
- SMA 50
- $12.41
- Price below SMA 50
- EMA 50
- $11.30
- Price below EMA 50
- SMA 200
- $8.34
- Price above SMA 200
- EMA 200
- $9.00
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $32.00
- Average
- $32.00
- High
- $32.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +19.9 | -0.1 | +26.7 | -25.8 | -16.2 |



